Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

0.4620 -0.0143 (-3.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 516,731
Open 0.4800
Bid (Size) 0.4559 (184)
Ask (Size) 0.4950 (25)
Prev. Close 0.4763
Today's Range 0.4550 - 0.4800
52wk Range 0.4508 - 2.550
Shares Outstanding 149,339,335
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Affimed to Present at the Cantor Global Healthcare Conference 2023
From Affimed N.V.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace

Performance

YTD
-61.82%
-61.82%
1 Month
-19.93%
-19.93%
3 Month
-28.96%
-28.96%
6 Month
-30.10%
-30.10%
1 Year
-77.24%
-77.24%

More News

Read More
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
From Affimed N.V.
Via GlobeNewswire
Expert Ratings for Affimed
Via Benzinga
Where Affimed Stands With Analysts
Via Benzinga
Affimed Earnings Preview
Via Benzinga
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
From Affimed N.V.
Via GlobeNewswire
Surprise! These 3 Penny Stocks Have Wall Street’s Seal of Approval.
Via InvestorPlace
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Analyst Ratings for Affimed
Via Benzinga
Affimed: Q1 Earnings Insights
Via Benzinga
3 Cheap Stocks to Buy Under $1 in August 2023
Via InvestorPlace
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
From Affimed N.V.
Via GlobeNewswire
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
From Affimed N.V.
Via GlobeNewswire
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the 2023 Jefferies Healthcare Conference
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For May 23, 2023
Via Benzinga
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
From Affimed N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.